Risk Factors for Discontinuation of S-1 Adjuvant Chemotherapy for Gastric Cancer
نویسندگان
چکیده
منابع مشابه
Risk Factors for Discontinuation of S-1 Adjuvant Chemotherapy for Gastric Cancer
PURPOSE The aim of this study was to clarify the risk factors for discontinuing tegafur/gimeracil/oteracil potassium (S-1) adjuvant chemotherapy following gastrectomy in patients with gastric cancer. METHODS We retrospectively investigated patients with curatively-resected gastric cancer who received S-1 adjuvant chemotherapy. S-1 was administered orally at 80-120 mg/day, depending on body su...
متن کاملAdjuvant S-1 chemotherapy after curative resection of gastric cancer.
To the Editor—In the February issue of Hong Kong Medical Journal, Yeo et al1 reported an informative study on the use of S-1 as adjunct chemotherapy after curative resection of gastric cancer. Since the active ingredient in S-1 is the prodrug tegafur, to be converted to 5-fluorouracil (5FU), much of the toxicity reduction depends on the degradation of 5FU by dihydropyrimidine dehydrogenase (DPD...
متن کاملChemotherapy for gastric cancer that recurs after adjuvant chemotherapy with S-1.
We retrospectively analyzed the efficacy of chemotherapy in patients whose gastric cancer recurred after adjuvant chemotherapy with S-1. A total of 51 patients were evaluated. Twenty-one patients received S-1-containing chemotherapy as first-line treatment after recurrence [cohort A: S-1 plus cisplatin (n = 10), S-1 monotherapy (n = 7), S-1 plus irinotecan (n = 3) and S-1 plus docetaxel (n = 1)...
متن کاملEvaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer
Gastric cancer (GC) is the second leading cause of cancer-related mortality worldwide. The usual treatment of GC consists of surgery with additional adjuvant chemotherapy. In the present study, the feasibility and safety of adjuvant S-1 plus oxaliplatin (SOX) chemotherapy for patients with GC and the optimal dosage of S-1 were determined. Eligible patients were randomly assigned to either arm A...
متن کاملDose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer.
Gastric cancer (GC) is the fourth most common type of cancer, accounting for an estimated one million new cases annually worldwide. Locally advanced GC often recurs, even following curative surgical resection. Therefore, there is a need for an effective adjuvant chemotherapy regimen. The aim of this trial was to investigate the maximum tolerated dose (MTD) of S-1 when administered in combinatio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Cancer
سال: 2015
ISSN: 1837-9664
DOI: 10.7150/jca.11189